Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia

Silvia De Sanjosé, Eva Hamsîíková, Nubia Muñoz, F. Xavier Bosch, Vanda Hofmannová, Miguel Gili, Isabel Izarzugaza, Pau Viladiu, Maria José Tormo, Pilar Moreo, Maria Teresa Muñoz, Nieves Ascunce, Luis Tafur, Keerti V. Shah, Vladimir Vonka

Research output: Contribution to journalArticle

Abstract

This study evaluates the association of antibodies against HPV-16-derived peptides with cervical cancer and estimates the sensitivity and specificity of the serological assays in relation to HPV DNA detection in cervical cells by PCR. Study subjects were derived from 4 case-control studies carried out in Spain and Colombia. Sera from 544 cases of CIN III and invasive cancer and of 543 age-matched controls were tested for antibodies to 5 peptides derived from E2, E7 (3 partially overlapping frames of HPV 16 denoted E7/1, E7/2, E7/3) and L2 open reading frames of HPV 16. HPV DNA was detected using a LI-PCR based method. Among cancer controls, antibody response to E2 and E7/1, E7/2, E7/3 was higher in Colombia (22.5%, 7.2%, 11.7%, 12.6% respectively) than in Spain (17.1%, 4.7%, 5.9%, 5.9%). E7 antibodies were related to stage, particularly in CIN III vs. invasive stages and less markedly within invasive stages. Detection of antibodies to the E7/1 was associated to CIN III (OR = 1.8). The risk of invasive cervical cancer was increased among those with antibodies to E2 (OR = 2.2), to E7/1 (OR = 4.2), to E7/2 (OR = 4.3), and to E7/3 (OR = 2.5). Presence of antibodies to all the 3 E7 peptides increased the risk of CIN III (OR = 5.6) and that of invasive cancer(OR = 17.5). High levels of antibodies to E7/1 or E7/2 or E7/3 increased the risk of invasive cervical cancer (OR for high levels of antibodies vs. negatives to E7/1 OR = 22.6; E7/2 OR = 7.5, E7/3 OR = 3.4). In the present analysis, antibodies to U were not associated with either CIN III or cervical cancer, Serological markers of HPV 16 detected less than half of the HPV-16-DNA-positive cases. It is concluded that antibodies to E2 and particularly E7 antigens are strongly associated with cervical cancer. Antibodies to E7 seem to be a moderate marker of tumor burden.

Original languageEnglish (US)
Pages (from-to)70-74
Number of pages5
JournalInternational Journal of Cancer
Volume66
Issue number1
DOIs
StatePublished - Mar 28 1996

Fingerprint

Colombia
Uterine Cervical Neoplasms
Spain
Case-Control Studies
Antibodies
Human papillomavirus 16
Peptides
DNA
Neoplasms
Polymerase Chain Reaction
Tumor Burden
Open Reading Frames
Antibody Formation
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia. / De Sanjosé, Silvia; Hamsîíková, Eva; Muñoz, Nubia; Bosch, F. Xavier; Hofmannová, Vanda; Gili, Miguel; Izarzugaza, Isabel; Viladiu, Pau; Tormo, Maria José; Moreo, Pilar; Muñoz, Maria Teresa; Ascunce, Nieves; Tafur, Luis; Shah, Keerti V.; Vonka, Vladimir.

In: International Journal of Cancer, Vol. 66, No. 1, 28.03.1996, p. 70-74.

Research output: Contribution to journalArticle

De Sanjosé, S, Hamsîíková, E, Muñoz, N, Bosch, FX, Hofmannová, V, Gili, M, Izarzugaza, I, Viladiu, P, Tormo, MJ, Moreo, P, Muñoz, MT, Ascunce, N, Tafur, L, Shah, KV & Vonka, V 1996, 'Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia', International Journal of Cancer, vol. 66, no. 1, pp. 70-74. https://doi.org/10.1002/(SICI)1097-0215(19960328)66:1<70::AID-IJC13>3.0.CO;2-F
De Sanjosé, Silvia ; Hamsîíková, Eva ; Muñoz, Nubia ; Bosch, F. Xavier ; Hofmannová, Vanda ; Gili, Miguel ; Izarzugaza, Isabel ; Viladiu, Pau ; Tormo, Maria José ; Moreo, Pilar ; Muñoz, Maria Teresa ; Ascunce, Nieves ; Tafur, Luis ; Shah, Keerti V. ; Vonka, Vladimir. / Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia. In: International Journal of Cancer. 1996 ; Vol. 66, No. 1. pp. 70-74.
@article{f6af7ffb5adf479596d91238849ad592,
title = "Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia",
abstract = "This study evaluates the association of antibodies against HPV-16-derived peptides with cervical cancer and estimates the sensitivity and specificity of the serological assays in relation to HPV DNA detection in cervical cells by PCR. Study subjects were derived from 4 case-control studies carried out in Spain and Colombia. Sera from 544 cases of CIN III and invasive cancer and of 543 age-matched controls were tested for antibodies to 5 peptides derived from E2, E7 (3 partially overlapping frames of HPV 16 denoted E7/1, E7/2, E7/3) and L2 open reading frames of HPV 16. HPV DNA was detected using a LI-PCR based method. Among cancer controls, antibody response to E2 and E7/1, E7/2, E7/3 was higher in Colombia (22.5{\%}, 7.2{\%}, 11.7{\%}, 12.6{\%} respectively) than in Spain (17.1{\%}, 4.7{\%}, 5.9{\%}, 5.9{\%}). E7 antibodies were related to stage, particularly in CIN III vs. invasive stages and less markedly within invasive stages. Detection of antibodies to the E7/1 was associated to CIN III (OR = 1.8). The risk of invasive cervical cancer was increased among those with antibodies to E2 (OR = 2.2), to E7/1 (OR = 4.2), to E7/2 (OR = 4.3), and to E7/3 (OR = 2.5). Presence of antibodies to all the 3 E7 peptides increased the risk of CIN III (OR = 5.6) and that of invasive cancer(OR = 17.5). High levels of antibodies to E7/1 or E7/2 or E7/3 increased the risk of invasive cervical cancer (OR for high levels of antibodies vs. negatives to E7/1 OR = 22.6; E7/2 OR = 7.5, E7/3 OR = 3.4). In the present analysis, antibodies to U were not associated with either CIN III or cervical cancer, Serological markers of HPV 16 detected less than half of the HPV-16-DNA-positive cases. It is concluded that antibodies to E2 and particularly E7 antigens are strongly associated with cervical cancer. Antibodies to E7 seem to be a moderate marker of tumor burden.",
author = "{De Sanjos{\'e}}, Silvia and Eva Hams{\^i}{\'i}kov{\'a} and Nubia Mu{\~n}oz and Bosch, {F. Xavier} and Vanda Hofmannov{\'a} and Miguel Gili and Isabel Izarzugaza and Pau Viladiu and Tormo, {Maria Jos{\'e}} and Pilar Moreo and Mu{\~n}oz, {Maria Teresa} and Nieves Ascunce and Luis Tafur and Shah, {Keerti V.} and Vladimir Vonka",
year = "1996",
month = "3",
day = "28",
doi = "10.1002/(SICI)1097-0215(19960328)66:1<70::AID-IJC13>3.0.CO;2-F",
language = "English (US)",
volume = "66",
pages = "70--74",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia

AU - De Sanjosé, Silvia

AU - Hamsîíková, Eva

AU - Muñoz, Nubia

AU - Bosch, F. Xavier

AU - Hofmannová, Vanda

AU - Gili, Miguel

AU - Izarzugaza, Isabel

AU - Viladiu, Pau

AU - Tormo, Maria José

AU - Moreo, Pilar

AU - Muñoz, Maria Teresa

AU - Ascunce, Nieves

AU - Tafur, Luis

AU - Shah, Keerti V.

AU - Vonka, Vladimir

PY - 1996/3/28

Y1 - 1996/3/28

N2 - This study evaluates the association of antibodies against HPV-16-derived peptides with cervical cancer and estimates the sensitivity and specificity of the serological assays in relation to HPV DNA detection in cervical cells by PCR. Study subjects were derived from 4 case-control studies carried out in Spain and Colombia. Sera from 544 cases of CIN III and invasive cancer and of 543 age-matched controls were tested for antibodies to 5 peptides derived from E2, E7 (3 partially overlapping frames of HPV 16 denoted E7/1, E7/2, E7/3) and L2 open reading frames of HPV 16. HPV DNA was detected using a LI-PCR based method. Among cancer controls, antibody response to E2 and E7/1, E7/2, E7/3 was higher in Colombia (22.5%, 7.2%, 11.7%, 12.6% respectively) than in Spain (17.1%, 4.7%, 5.9%, 5.9%). E7 antibodies were related to stage, particularly in CIN III vs. invasive stages and less markedly within invasive stages. Detection of antibodies to the E7/1 was associated to CIN III (OR = 1.8). The risk of invasive cervical cancer was increased among those with antibodies to E2 (OR = 2.2), to E7/1 (OR = 4.2), to E7/2 (OR = 4.3), and to E7/3 (OR = 2.5). Presence of antibodies to all the 3 E7 peptides increased the risk of CIN III (OR = 5.6) and that of invasive cancer(OR = 17.5). High levels of antibodies to E7/1 or E7/2 or E7/3 increased the risk of invasive cervical cancer (OR for high levels of antibodies vs. negatives to E7/1 OR = 22.6; E7/2 OR = 7.5, E7/3 OR = 3.4). In the present analysis, antibodies to U were not associated with either CIN III or cervical cancer, Serological markers of HPV 16 detected less than half of the HPV-16-DNA-positive cases. It is concluded that antibodies to E2 and particularly E7 antigens are strongly associated with cervical cancer. Antibodies to E7 seem to be a moderate marker of tumor burden.

AB - This study evaluates the association of antibodies against HPV-16-derived peptides with cervical cancer and estimates the sensitivity and specificity of the serological assays in relation to HPV DNA detection in cervical cells by PCR. Study subjects were derived from 4 case-control studies carried out in Spain and Colombia. Sera from 544 cases of CIN III and invasive cancer and of 543 age-matched controls were tested for antibodies to 5 peptides derived from E2, E7 (3 partially overlapping frames of HPV 16 denoted E7/1, E7/2, E7/3) and L2 open reading frames of HPV 16. HPV DNA was detected using a LI-PCR based method. Among cancer controls, antibody response to E2 and E7/1, E7/2, E7/3 was higher in Colombia (22.5%, 7.2%, 11.7%, 12.6% respectively) than in Spain (17.1%, 4.7%, 5.9%, 5.9%). E7 antibodies were related to stage, particularly in CIN III vs. invasive stages and less markedly within invasive stages. Detection of antibodies to the E7/1 was associated to CIN III (OR = 1.8). The risk of invasive cervical cancer was increased among those with antibodies to E2 (OR = 2.2), to E7/1 (OR = 4.2), to E7/2 (OR = 4.3), and to E7/3 (OR = 2.5). Presence of antibodies to all the 3 E7 peptides increased the risk of CIN III (OR = 5.6) and that of invasive cancer(OR = 17.5). High levels of antibodies to E7/1 or E7/2 or E7/3 increased the risk of invasive cervical cancer (OR for high levels of antibodies vs. negatives to E7/1 OR = 22.6; E7/2 OR = 7.5, E7/3 OR = 3.4). In the present analysis, antibodies to U were not associated with either CIN III or cervical cancer, Serological markers of HPV 16 detected less than half of the HPV-16-DNA-positive cases. It is concluded that antibodies to E2 and particularly E7 antigens are strongly associated with cervical cancer. Antibodies to E7 seem to be a moderate marker of tumor burden.

UR - http://www.scopus.com/inward/record.url?scp=9244244182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244244182&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960328)66:1<70::AID-IJC13>3.0.CO;2-F

DO - 10.1002/(SICI)1097-0215(19960328)66:1<70::AID-IJC13>3.0.CO;2-F

M3 - Article

C2 - 8608970

AN - SCOPUS:9244244182

VL - 66

SP - 70

EP - 74

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -